Clinical Trials Logo

Clinical Trial Summary

This is a multicentre, paired-cohort, prospective, controlled study. The patient with a suspicion of PCa and a concomitant positive mpMRI (defined as presence of one lesion PI-RADS ≥ 3) will receive a MRI-TBx (4 target cores). During the same session, subsequently to MRI-TBx, patient will receive a systematic sampling with 6-core S-Bx followed by 14-core S-Bx, for a total of 20-core systematic cores, in addition to 4 MRI-TBx cores. Procedure will be performed by the same operator. Each single core will be stored in a dedicated cassette and sequentially numbered. We hypothesize that the proportion of csPCa (defined as prostate cancer with Gleason score ≥ 3+4) detected by 6-cores S-Bx will be no less than that detected by 20-cores S-Bx, both performed in addition to MRI-TBx. Assessing the optimal number of systematic cores to take in addition to MRI-TBx cores in men undergoing a MRI-TBx would provide a useful clinical information for every day clinical practice. Moreover, the possibility to decrease the number of systematic cores taken during a MRI-TBx, hence reducing the overall number of cores taken during a biopsy, would reduce the length of the diagnostic procedure, potentially reduce the probability of infections/sepsis and reduce the overdiagnosis of clinically insignificant PCa.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms

  • Prostatic Neoplasms
  • Suspicion of Prostate Cancer With a Positive Multiparametric Magnetic Resonance of the Prostate

NCT number NCT04183699
Study type Interventional
Source IRCCS San Raffaele
Contact Armando Stabile
Phone +390226435660
Email stabile.armando@hsr.it
Status Recruiting
Phase N/A
Start date June 6, 2019
Completion date June 30, 2025